Novo Holdings Acquires BBI Group

Novo Holdings to Acquire Benchmark Genetics

November 25, 2024

Biotechnology

Novo Holdings agreed to acquire Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million. Completion is expected in the first quarter of 2025, subject to shareholder approval and regulatory clearances, with initial consideration of £230 million plus up to £30 million contingent on revenue thresholds.

Novo Holdings Invests £50m in Oxford Nanopore Technologies

August 1, 2024

Biotechnology

Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

BBI Solutions Acquires IBEX Technologies Inc.

April 8, 2024

Biotechnology

BBI Solutions OEM Limited has acquired IBEX Technologies Inc., a Montreal-based developer and manufacturer of high-precision enzymes and diagnostic solutions, with the transaction closing on April 8, 2024. The acquisition expands BBI's recombinant protein and enzyme capabilities to better serve in-vitro diagnostics (IVD) manufacturers and brings IBEX's staff and contract-manufacturing capabilities into BBI's global operations.

Novo Holdings Acquires Ellab from EQT Private Equity

June 21, 2023

Medical Devices

Novo Holdings A/S has agreed to acquire Ellab from EQT Mid Market Europe (EQT Private Equity); the deal was announced in June and subsequently completed following regulatory approvals. Headquartered in Hillerød, Denmark, Ellab is a provider of validation and monitoring hardware, software and services for the biotech and pharmaceutical industries; the Lundbeck Foundation has also agreed to acquire a significant minority stake.

Venture Life Group plc Acquires BBI Healthcare (BBIH) from Exponent

June 7, 2021

Consumer Products

Venture Life Group plc has agreed to acquire BBI Healthcare (BBIH), the consumer self-care division of BBI Group, from private equity owner Exponent. BBIH — owner of brands including Balance Activ, GlucoGel and LIFT with broad UK retail distribution and a Swedish manufacturing facility — was transformed under Exponent, delivering strong EBITDA growth; its managing director will leave on completion while the chairman will remain with BBI Group.

Novo Holdings Invests in Oxford Biomedica plc

May 28, 2019

Biotechnology

Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.